Syneos Health Announces Secondary Offering of Common Stock
August 06 2018 - 3:33PM
Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos
Health”), a leading biopharmaceutical solutions organization
combining a CRO (Contract Research Organization) and a CCO
(Contract Commercial Organization), today announced that affiliates
of Thomas H. Lee Partners, L.P. intend to offer for sale in an
underwritten secondary offering 6,000,000 shares of the Company’s
common stock (the “Offering”) pursuant to the Company’s shelf
registration statement filed with the Securities and Exchange
Commission (“SEC”). Syneos Health will not receive any proceeds
from the sale of the shares by the selling stockholders in the
Offering.
Morgan Stanley is acting as the sole underwriter of the
Offering.
An automatic shelf registration statement (including a
prospectus) relating to the offering of common stock was filed with
the SEC on December 1, 2015 and became effective upon filing.
Before you invest, you should read the registration statement,
prospectus, prospectus supplement and other documents Syneos Health
has made available with the SEC for information about Syneos Health
and the Offering. You may obtain these documents free of charge by
visiting EDGAR on the SEC website at www.sec.gov. Alternatively,
copies of the prospectus and accompanying prospectus supplement,
when available, may be obtained from: Morgan Stanley & Co.
LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New
York, NY 10014.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or other jurisdiction in which such
an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or other jurisdiction.
Forward-Looking Statements
Except for historical information, all of the statements,
expectations, and assumptions contained in this press release are
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. Actual results might
differ materially from those explicit or implicit in the
forward-looking statements. Important factors that could cause
actual results to differ materially include, but are not limited
to: risks associated with the integration of the Company's business
with the business of inVentiv Health and its operation of the
combined business following the closing of the merger with inVentiv
Health in August 2017; the Company's ability to maintain or
generate new business awards; the Company's ability to increase its
market share, grow its business, and execute its growth strategies;
the Company's backlog not being indicative of future revenues and
its ability to realize the anticipated future revenue reflected in
its backlog; the impact of adoption of the new accounting standard
of recognizing revenue from customers; the impact of the Tax Cuts
and Jobs Act; the Company's ability to adequately price its
contracts and not overrun cost estimates; general and international
economic, political, and other risks, including currency and stock
market fluctuations and the uncertain economic environment;
fluctuations in the Company's financial results; reliance on key
personnel; customer or therapeutic area concentration; and the
other risk factors set forth in the Company's Annual Report on Form
10-K for the fiscal year ended December 31, 2017 and other SEC
filings, copies of which are available free of charge on the
Company's website at investor.syneoshealth.com. Syneos Health
assumes no obligation and does not intend to update these
forward-looking statements, except as required by law.
About Syneos Health
Syneos Health (Nasdaq:SYNH) is the only fully integrated
biopharmaceutical solutions organization. The Company, including a
Contract Research Organization (CRO) and Contract Commercial
Organization (CCO), is purpose-built to accelerate customer
performance to address modern market realities. Created through the
merger of two industry leading companies – INC Research and
inVentiv Health – Syneos Health brings together more than 21,000
clinical and commercial minds with the ability to support customers
in more than 110 countries. The Company shares insights, uses the
latest technologies and applies advanced business practices to
speed customers’ delivery of important therapies to patients.
|
|
|
Investor Relations
Contact: |
|
Press/Media
Contact: |
Ronnie SpeightVice
President, Investor RelationsPhone: +1 919 745 2745Email:
Investor.Relations@syneoshealth.com |
|
Danielle DeForgeExecutive
Director, External CommunicationsPhone: +1 781 425 2624Email:
danielle.deforge@syneoshealth.com |
|
|
|
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Syneos Health (NASDAQ:SYNH)
Historical Stock Chart
From Jul 2023 to Jul 2024